Nuclear genes commonly involved in progression from hyperplasia to tumor (KRAS, PTEN, TP53 and CTNNB1) were screened for point mutations in the hyperplastic and tumor samples of the same patients in order to place mtDNA mutations in the EC tumor progression model [39]. This evidence concerns the gene KRAS and neoplasm.